Pharma

tough-times-ahead-for-merck-r-d-personnel-as-the-firm-plans-to-axe-several-jobs

Report: Merck to axe several R&D jobs

  • US
  • |
  • News

Singapore: Merck & Co plans to cut jobs at its research laboratories in order to simplify governance so as to advance therapeutic and vaccine candidates more efficiently and focus resources on the most promising programs. The move comes... Read more

duke-cancer-institute-atudy-pfizer-s-osteoporosis-drug-bazedoxifene-can-stop-even-the-most-resistant-breast-cancers

Osteoporosis drug can kill resistant cancer


  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: A research by Duke Cancer Institute has shown that osteoporosis drug bazedoxifene stops the growth of breast cancer... Read more

equipment

Wohl begins to buy & sell used pharma equipments


  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: US market leader in used processing and packagng industries, Wohl Associates, has begun to sell used pharmaceutical... Read more

horizon-managing-director-aiden-corcoran

Irish firm's track-&-trace system to curb fake drugs

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Horizon, an Irish engineerng consultancy firm, has completed testing of its new tracking system that aims at eliminating the... Read more

hope-for-alzheimer-s-and-parkinson-s-patients-university-college-london-ucl-and-eisai-form-research-alliance-therapeutic-innovation-group-tig

Shionogi partners with six Irish universities

  • Japan
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Shionogi, one of Japan's biggest pharmaceutical companies, has signed a memorandum of understanding (MoU) for an R&D partnership... Read more

sodium-tablets-generic

Daiichi Sankyo files NDA for Prasugrel in Japan

  • Japan
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Japanese drug major Daiichi Sankyo submitted a New Drug Application to the Ministry of Health, Labor and Welfare in Japan for... Read more

the-japanese-government-astellas-eisai-daiichi-sankyo-shionogi-takeda-and-bill-melinda-gates-foundation-will-initiate-an-effort-worth-usd100-million-to-tackle-hiv-malaria-tuberculosis-and-tropical-diseas

Astellas looks to sell dermatology assets: Sources

  • Japan
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Japan-based drugmaker Astellas Pharma is planning to sell its dermatology portfolio, which could be worth between $500 million... Read more

ms-nandita-singh-editor-biospectrum-asia

Is China bioscience really slowing down?

  • China
  • |
  • Opinion
  • |
  • By Nandita Singh
  • |
  • 1 Comment

Is China bioscience slowing down? From the numbers that have been put together by the BioSpectrum Asia Pacific Bioscience Industry Survey... Read more

parkinsons-disease11

Aus pharma benefit scheme includes Parkinson's drug

  • Australia
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: The Australian Pharmaceutical Benefits Scheme has listed a novel treatment for Parkinson's disease in order to make it available... Read more

good-news-for-alzheimer-s-disease-patients-shasun-and-debiopharm-will-manufacture-brain-drug-huperzine-a

Japan approves Avastin for brain cancer treatment

  • Japan
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Roche announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Avastin (bevacizumab) for the treatment... Read more

j-j-acquires-aragon-and-its-androgen-receptor-antagonist-program-including-cancer-drug-arn-509-a-second-generation-androgen-receptor-signaling-inhibitor-currently-in-phase-ii-trial

J&J to acquire cancer drug firm for $1 bn

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Johnson & Johnson is going to acquire US-based Aragon Pharmaceuticals for $650 million in cash up front along with $350 million... Read more

dr-habil-khorakiwala-chairman-wockhardt-fears-that-the-firm-may-lose-usd100-million-in-sales-due-to-the-ban-by-indian-authorities

Wockhardt chairman: Painkiller ban may cost us $100 mn

  • India
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: The several bans on Proxyvon, a brand under India-based Wockhardt sold formulation of the painkiller dextropropoxyphene, has... Read more

Previous 1 3 4 5 6 7

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X